Breakthrough T1D Encouraged by Promising Results of FINE-ONE Phase 3 Clinical Trial Evaluating Finerenone for Chronic Kidney Disease Associated with Type 1 Diabetes
Results from the Bayer-led Phase 3 FINE-ONE clinical trial, presented at the American Society of Nephrology Kidney Week in Houston, revealed that finerenone significantly reduced the urine albumin-to-creatinine ratio (UACR) over six months in adults with chronic kidney disease (CKD) linked to type 1 diabetes (T1D).
A decrease in UACR is commonly associated with slower CKD progression, better kidney function, and a reduced risk of cardiovascular problems. CKD continues to pose a serious threat to people living with T1D, affecting nearly one in three individuals during their lifetime.
Finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), is currently approved for adults with CKD linked to type 2 diabetes. The new FINE-ONE trial results suggest its potential effectiveness for CKD associated with T1D as well. Bayer plans to submit the data to health authorities for regulatory review.
"We are thrilled to see the results from FINE-ONE showing that finerenone improved kidney health in people with type 1 diabetes and chronic kidney disease," said Jonathan Rosen, Ph.D., Research Director at Breakthrough T1D.
Key Highlights
- Finerenone reduced UACR levels in six months among CKD and T1D patients.
- Results indicate potential to delay CKD progression and support kidney health.
- Bayer aims to seek regulatory approval for finerenone in CKD linked to T1D.
Author Summary: The FINE-ONE trial shows finerenone’s promise in improving kidney outcomes for adults with type 1 diabetes and chronic kidney disease, marking a major step in diabetic nephropathy treatment.